Back to top anchor

Australasian COVID-19 Trial (ASCOT)

Year:
2020
Duration:
24 months
Approved budget:
$766,113.00
Researchers:
Dr Susan Morpeth
,
Associate Professor Steven Tong
,
Assistant Professor Justin Denholm
,
Dr Michael Maze
,
Dr Colin McArthur
,
Dr David Price
,
Dr Stephen Ritchie
,
Dr Ayesha Verrall
,
Dr Catherina Chang
,
Dr Alex Semprini
,
Dr Thomas Hills
,
Dr Jack Dummer
,
Dr Stephen Hogg
,
Dr Sandra Hotu
Health issue:
Infectious disease
Proposal type:
Project
Lay summary
ASCOT is an open label randomised controlled trial of unproven treatments for pandemic coronavirus infection among people unwell enough to need admission to hospital, but not so unwell that they need intensive care. Consenting participants will be randomised to either lopinavir-ritonavir (an anti-viral used to treat HIV), hydroxychloroquine (used in autoimmune diseases), both of these agents in combination, or the current standard of care. The study will be carried out at multiple sites across Australia and New Zealand. We will see whether either or both of these potential treatments will reduce the risk of needing intensive care or death from pandemic coronavirus infection.